Recent News

• 03.18.2026 - Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis
• 02.26.2026 - Aclaris Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Recent Filings

• 03.11.2026 - 8-K Current report
• 03.10.2026 - 8-K Current report
• 03.03.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.26.2026 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 02.26.2026 - 8-K Current report
• 02.26.2026 - EX-99.1 EX-99.1
• 02.09.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.06.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.06.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.06.2026 - 4 Statement of changes in beneficial ownership of securities